| Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II Trial | Entinostat | Phase 2 | Not yet recruiting | Shu Zhao | Nov 16, 2026 |
| Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities | Entinostat | Phase 1 | Recruiting | Beijing Tongren Hospital | Oct 22, 2026 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | Entinostat | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | Jul 16, 2026 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | Belinostat | Phase 1 | Recruiting | City of Hope Medical Center | Jul 9, 2026 |
| Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | Entinostat | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | Mar 25, 2026 |
| A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer | Entinostat | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | Mar 2, 2026 |
| A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy | Entinostat | Phase 2 | Recruiting | Zhejiang Cancer Hospital | Jan 9, 2026 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | Entinostat | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Dec 3, 2025 |
| A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer | Entinostat | Phase 2 | Not yet recruiting | Sun Yat-sen University | Nov 19, 2025 |
| A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy | Givinostat | — | Recruiting | ITF Therapeutics LLC | Aug 17, 2025 |
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | Romidepsin | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | May 9, 2025 |
| Adjuvant Quisinostat in High-Risk Uveal Melanoma | Quisinostat | Phase 2 | Recruiting | University of Miami | Apr 17, 2025 |
| DMD Voice: Qualitative Interviews With Patients and Caregivers | Givinostat | — | Recruiting | Red Nucleus Enterprise Solutions, LLC | Apr 13, 2025 |
| Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas | Quisinostat | Early phase 1 | Active, not recruiting | Nader Sanai | Feb 13, 2025 |
| Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old | Givinostat | Phase 2 | Recruiting | Italfarmaco | Jan 10, 2025 |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Belinostat | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | Aug 19, 2024 |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | Belinostat | Phase 2 | Recruiting | National Cancer Institute (NCI) | May 9, 2024 |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Givinostat | Phase 3 | Recruiting | Italfarmaco | Oct 23, 2023 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Belinostat | Phase 3 | Active, not recruiting | Acrotech Biopharma Inc. | Oct 10, 2023 |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease | Fimepinostat | Phase 2 | Recruiting | University of California, Los Angeles | Aug 2, 2023 |
| Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy | Givinostat | Phase 3 | Recruiting | Italfarmaco | Jul 6, 2023 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | Panobinostat | Phase 2 | Recruiting | Oslo University Hospital | Feb 13, 2023 |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | Abexinostat | Phase 1 | Recruiting | University of Nebraska | Jan 26, 2023 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | Belinostat | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Nov 25, 2022 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | Belinostat | Phase 2 | Active, not recruiting | H. Lee Moffitt Cancer Center and Research Institute | Dec 27, 2021 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL | Belinostat, Romidepsin | Phase 2 | Recruiting | University of Virginia | Feb 10, 2021 |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | Belinostat | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Apr 10, 2020 |
| A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients | Abexinostat | Phase 1 / Phase 2 | Active, not recruiting | Xynomic Pharmaceuticals, Inc. | Jul 18, 2019 |
| Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Abexinostat | Phase 2 | Recruiting | Xynomic Pharmaceuticals, Inc. | May 3, 2019 |
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | Abexinostat | Phase 2 | Active, not recruiting | Xynomic Pharmaceuticals, Inc. | May 2, 2019 |
| Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma | Abexinostat | Phase 2 | Active, not recruiting | Xynomic Pharmaceuticals, Inc. | Jul 26, 2018 |
| A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Abexinostat | Phase 3 | Recruiting | Xynomic Pharmaceuticals, Inc. | Jul 19, 2018 |
| Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study | Givinostat | Phase 2 / Phase 3 | Recruiting | Italfarmaco | Dec 14, 2017 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | Romidepsin | Phase 1 / Phase 2 | Recruiting | University of Virginia | May 19, 2017 |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Romidepsin | Phase 1 / Phase 2 | Active, not recruiting | Priyanka Sharma | Mar 19, 2015 |
| CINC424A2X01B Rollover Protocol | Panobinostat | Phase 4 | Active, not recruiting | Novartis Pharmaceuticals | Mar 12, 2015 |
| Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | Givinostat | Phase 2 | Active, not recruiting | Italfarmaco | Jan 7, 2013 |
| Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease | Panobinostat | Phase 1 | Recruiting | Abdullah Kutlar | Nov 22, 2010 |